Q4 2024 Vericel Corp Earnings Call Transcript
Key Points
- Vericel Corp (VCEL) achieved a 20% total revenue growth in 2024, reaching over $237 million.
- The company reported record quarterly revenue of over $75 million in the fourth quarter, with a gross margin of 78%.
- MACI's fourth-quarter revenue grew by 21% year-over-year and 53% sequentially, driven by strong fundamentals and increased surgeon engagement.
- The Burn Care franchise saw a 22% revenue increase in 2024, with Nexobrid hospital orders rising by 42% in the fourth quarter.
- Vericel Corp (VCEL) achieved GAAP profitability for the year, with net income of $10.4 million, and operating cash flow increased to nearly $60 million.
- Epicel revenue was below recent run rates in the fourth quarter due to fewer patient treatments and grafts per patient.
- Operating expenses increased to $167.6 million in 2024, primarily due to development and commercial launch activities.
- The company anticipates a significant decrease in capital expenditures in 2025, which may impact future growth investments.
- The guidance for 2025 includes a potential impact on margins due to the completion of the new facility, which will add $10 million in incremental expenses.
- The MACI Arthro launch is still in its early stages, and significant contributions to revenue growth are not yet factored into the 2025 guidance.
Good day and thank you for standing by. Welcome to the Vericel Corporation 4th quarter 2024 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [operator instruction]
I would now like to hand the conference over to your first speaker today, Eric Burns, Vice President of Finance and investor relations. Please go ahead.
Thank you, operator, and good morning, everyone. Joining me on today's call are Vericel President and Chief Executive Officer Nick Colangelo and our Chief Financial Officer Joe Mora. Before we begin, let me remind you that on today's call, we will be making forward-looking statements covered under the Private Securities Litigation Reform Act of 1,995.
These statements may involve risks and uncertainties that could cause actual results to firm some expectations. And I just more fully in our follows with the SEC. In addition, all forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
